Literature DB >> 23239797

Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

R L Brocato1, M J Josleyn, V Wahl-Jensen, C S Schmaljohn, J W Hooper.   

Abstract

Puumala virus (PUUV) is a causative agent of hemorrhagic fever with renal syndrome (HFRS). Although PUUV-associated HFRS does not result in high case-fatality rates, the social and economic impact is considerable. There is no licensed vaccine or specific therapeutic to prevent or treat HFRS. Here we report the synthesis of a codon-optimized, full-length M segment open reading frame and its cloning into a DNA vaccine vector to produce the plasmid pWRG/PUU-M(s2). pWRG/PUU-M(s2) delivered by gene gun produced high-titer neutralizing antibodies in hamsters and nonhuman primates. Vaccination with pWRG/PUU-M(s2) protected hamsters against infection with PUUV but not against infection by related HFRS-associated hantaviruses. Unexpectedly, vaccination protected hamsters in a lethal disease model of Andes virus (ANDV) in the absence of ANDV cross-neutralizing antibodies. This is the first evidence that an experimental DNA vaccine for HFRS can provide protection in a hantavirus lethal disease model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239797      PMCID: PMC3571280          DOI: 10.1128/CVI.00546-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  41 in total

1.  Isolation of virus causing hemorrhagic fever with renal syndrome (HFRS) through a cell culture system.

Authors:  T Kitamura; C Morita; T Komatsu; K Sugiyama; J Arikawa; S Shiga; H Takeda; Y Akao; K Imaizumi; A Oya; N Hashimoto; S Urasawa
Journal:  Jpn J Med Sci Biol       Date:  1983-02

2.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Nucleotide and deduced amino acid sequences of the M and S genome segments of two Puumala virus isolates from Russia.

Authors:  S Y Xiao; K W Spik; D Li; C S Schmaljohn
Journal:  Virus Res       Date:  1993-10       Impact factor: 3.303

4.  Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica).

Authors:  K B Sjölander; F Elgh; H Kallio-Kokko; O Vapalahti; M Hägglund; V Palmcrantz; P Juto; A Vaheri; B Niklasson; A Lundkvist
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

5.  Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes.

Authors:  F Elgh; A Lundkvist; O A Alexeyev; H Stenlund; T Avsic-Zupanc; B Hjelle; H W Lee; K J Smith; R Vainionpää; D Wiger; G Wadell; P Juto
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

6.  Serotypic classification of hantaviruses by indirect immunofluorescent antibody and plaque reduction neutralization tests.

Authors:  P W Lee; C J Gibbs; D C Gajdusek; R Yanagihara
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

7.  Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: identification of epitopes involved in neutralization.

Authors:  A Lundkvist; B Niklasson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Nephropathia epidemica in Finland: a retrospective study of 126 cases.

Authors:  J Mustonen; M Brummer-Korvenkontio; K Hedman; A Pasternack; K Pietilä; A Vaheri
Journal:  Scand J Infect Dis       Date:  1994

9.  Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia.

Authors:  T Avsic-Zupanc; S Y Xiao; R Stojanovic; A Gligic; G van der Groen; J W LeDuc
Journal:  J Med Virol       Date:  1992-10       Impact factor: 2.327

10.  A macaque model for hantavirus infection.

Authors:  J Groen; M Gerding; J P Koeman; P J Roholl; G van Amerongen; H G Jordans; H G Niesters; A D Osterhaus
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

View more
  18 in total

1.  Hantavirus Gn and Gc glycoproteins self-assemble into virus-like particles.

Authors:  Rodrigo Acuña; Nicolás Cifuentes-Muñoz; Chantal L Márquez; Manuela Bulling; Jonas Klingström; Roberta Mancini; Pierre-Yves Lozach; Nicole D Tischler
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

2.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Hantavirus entry: Perspectives and recent advances.

Authors:  Eva Mittler; Maria Eugenia Dieterle; Lara M Kleinfelter; Megan M Slough; Kartik Chandran; Rohit K Jangra
Journal:  Adv Virus Res       Date:  2019-08-07       Impact factor: 9.937

4.  A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Authors:  Rebecca L Brocato; Christopher D Hammerbeck; Todd M Bell; Jay B Wells; Laurie A Queen; Jay W Hooper
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

5.  A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Authors:  Jay W Hooper; Matthew Josleyn; John Ballantyne; Rebecca Brocato
Journal:  Vaccine       Date:  2013-07-24       Impact factor: 3.641

6.  Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection.

Authors:  Taylor B Engdahl; Natalia A Kuzmina; Adam J Ronk; Chad E Mire; Matthew A Hyde; Nurgun Kose; Matthew D Josleyn; Rachel E Sutton; Apoorva Mehta; Rachael M Wolters; Nicole M Lloyd; Francisca R Valdivieso; Thomas G Ksiazek; Jay W Hooper; Alexander Bukreyev; James E Crowe
Journal:  Cell Rep       Date:  2021-05-04       Impact factor: 9.423

Review 7.  Immune response during hantavirus diseases: implications for immunotherapies and vaccine design.

Authors:  Farides Saavedra; Fabián E Díaz; Angello Retamal-Díaz; Camila Covián; Pablo A González; Alexis M Kalergis
Journal:  Immunology       Date:  2021-03-18       Impact factor: 7.215

Review 8.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses.

Authors:  Joseph W Golden; Christopher D Hammerbeck; Eric M Mucker; Rebecca L Brocato
Journal:  Biomed Res Int       Date:  2015-07-21       Impact factor: 3.411

9.  Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Authors:  Monica Ogg; Colleen B Jonsson; Jeremy V Camp; Jay W Hooper
Journal:  Viruses       Date:  2013-11-08       Impact factor: 5.048

10.  The use of chimeric virus-like particles harbouring a segment of hantavirus Gc glycoprotein to generate a broadly-reactive hantavirus-specific monoclonal antibody.

Authors:  Aurelija Zvirbliene; Indre Kucinskaite-Kodze; Ausra Razanskiene; Rasa Petraityte-Burneikiene; Boris Klempa; Rainer G Ulrich; Alma Gedvilaite
Journal:  Viruses       Date:  2014-02-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.